Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment

Biomarkers in Medicine

Volumn 4, Issue 4, 2010, Pages 535-541

  Jiang, Yixing ^a   MacKley, Heath ^a   Cheng, Hua ^a   Ajani, Jaffer A ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

anti EGFR treatment; K Ras; mutation; predictive biomarker

Indexed keywords

B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; K RAS PROTEIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO;

CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; GENE MUTATION; HUMAN; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUTATIONAL ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; GENES, RAS; HUMANS; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 77955651659     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.74     Document Type: Review

References (40)

1. Kirsten WH, Mayer LA: Morphologic responses to a murine erythroblastosis virus. J. Natl Cancer Inst. 39(2), 311-335 (1967)
2. Santos E, Martin-Zanca D, Reddy EP, Pierotti MA, Della Porta G, Barbacid M: Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223(4637), 661-664 (1984)
3. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL: Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N. Engl. J. Med. 317(15), 929-935 (1987)
4. Bos JL, Fearon ER, Hamilton SR et al.: Prevalence of ras gene mutations in human colorectal cancers. Nature 327(6120), 293-297 (1987)
5. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M: Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327(6120), 298-303 (1987)
6. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53(4), 549-554 (1988)
7. Messa C, Russo F, Caruso MG, Di Leo A: EGF, TGF-a, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 37(3), 285-289 (1998)
8. Porebska I, Harlozinska A, Bojarowski T: Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 21(2), 105-115 (2000)
9. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71(8), 2454-2460 (1993)
10. Cunningham D, Humblet Y, Siena S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004)
11. Van Cutsem E, Geboes K: The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. Best Pract. Res. 21(6), 1089-1108 (2007)
12. Personeni N, De Schutter J, De Hertogh G et al.: Response prediction to cetuximab-based therapy: the role of EGFR copy number by fluorescence in situ hybridization and downstream effectors gene mutations. Presented at: 2007 Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19-21 January, 2007
13. Finocchiaro G, Cappuzzo F, Jänne PA et al.: EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. J. Clin. Oncol. 25, 4021 (2007)
14. De Rook W, De Schutter J, De Hertogh G et al.: KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab. J. Clin. Oncol. 4132(25), 4132 (2007)
15. De Roock W, Piessevaux H, De Schutter J et al.: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19(3), 508-515 (2008)
16. Karapetis CS, Khambata-Ford S, Jonker DJ et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer N. Engl. J. Med. 359(17), 1757-1765 (2008)
17. Amado RG, Wolf M, Peeters M et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008)
18. Viret F, Smedra BT, Esteyries S et al.: Genetic predictors of cetuximab response in metastatic colorectal cancer. Presented at: 2008 Gastrointestinal Cancers Symposium. FL, USA, 25-27 January 2008 (Abstract 438)
19. Stoehlmacher J, Mogck U, Jakob C et al.: KRAS mutations, EGFR polymorphisms, and polymorphisms of immunoglobulin fragment C receptor as predictors for response to cetuximab containing chemotherapy in colorectal cancer patients. Identification of new KRAS mutation in codon 12. Presented at: 2008 Gastrointestinal Cancers Symposium. FL, USA, 25-27 January 2008 (Abstract 410).
20. Bokemeyer C, Bondarenko I, Hartmann JT et al.: KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOXwith or without cetuximab: the OPUS experience. J. Clin. Oncol. 26 (Suppl.), 178S (2008) (Abstract 4000)
21. Van Cutsem E, Lang I, Dhaens G et al.: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J. Clin. Oncol. 26(Suppl.), 15S (2008)
22. Tejpar S, Peeters M, Humblet Y et al.: Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): the EVEREST experience (preliminary data). J. Clin. Oncol. 26(Suppl.), 15S (2008) (Abstract 4001)
23. Loupakis F, Pollina L, Stasi G et al.: Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment. J. Clin. Oncol. 26(Suppl.), 178S (2008) (Abstract 4003)
24. Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D: Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate 68(9), 935-944 (2008)
25. Davies H, Bignell GR, Cox C et al.: Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002)
26. Barault L, Veyrie N, Jooste V et al.: Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int. J. Cancer 122(10), 2255-2259 (2008)
27. Pirker R, Pereira JR, Szczesna A et al.: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised Phase III trial. Lancet 373(9674), 1525-1531 (2009)
28. Lynch TJ, Patel T, Dreisbach L et al.: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter Phase III trial BMS099. J. Clin. Oncol. 28(6), 911-917 (2010)
29. Khambata-Ford S, Harbison CT, Hart LL et al.: Analysis of potential predictive markers of cetuximab benefit in BMS099, a Phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 28(6), 918-927 (2010)
30. OByrne KJ, Bondarenko I, Barrios C et al.: Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study. J. Clin. Oncol. 27(Suppl.), 15S (2009) (Abstract 8007)
31. Mack PC, Holland WS, Redman M et al.: KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. J. Clin. Oncol. 27(Suppl.), 15S (2009) (Abstract 8022)
32. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005)
33. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004)
34. Paez JG, Janne PA, Lee JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004)
35. Tiseo M, Rossi G, Capelletti M et al.: Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer 67(3), 355-360 (2010)
36. Linardou H, Dahabreh IJ, Kanaloupiti D et al.: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9(10), 962-972 (2008)
37. Kalikaki A, Koutsopoulos A, Trypaki M et al.: Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br. J. Cancer 99(6), 923-929 (2008)
38. Ince WL, Jubb AM, Holden SN et al.: Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J. Natl Cancer Inst. 97(13), 981-989 (2005)
39. Downward J: Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3(1), 11-22 (2003)
40. Amado RG, Wolf M, Freeman D et al.: Panitumumab (PMAB) efficacy and patient-reported outcomes (PRO) in metastatic colorectal cancer (mCRC) patients (pts) with wild-type (WT) KRAS tumor status. Presented at: 2008 Gastrointestinal Cancers Symposium. FL , USA, 25-27 January 2008 (Abstract 278)